Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary
NCT07761429Phase 3Recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of rulonilimab in cancer of unknown primary (CUP), sponsored by Shandong New Time Pharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
rulonilimab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT07761429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07761429.